Thiogenesis says FDA clears IND for cystinosis drug TTI-0102

Thiogenesis Therapeutics says the FDA cleared its Investigational New Drug application for TTI-0102 to treat nephropathic cystinosis, issuing a 'Study May Proceed' letter for IND 184780 on October 16, 2026. The clearance supports investigator-initiated study TTI-CYST-001 at Emory University and Children's Healthcare of Atlanta.

Detected & updated continuously · Source: Nebula